Claims
- 1. An isolated nucleic acid sequence coding for B lymphocyte activation antigen, B7.
- 2. An isolated nucleic acid sequence according to claim 1, wherein the nucleic acid sequence is a cDNA sequence.
- 3. An isolated nucleic acid sequence according to claim 2, wherein the DNA is of human origin.
- 4. An isolated nucleic acid sequence according to claim 2, wherein the DNA is of murine origin.
- 5. An isolated nucleic acid sequence according to claim 4, wherein the DNA of murine origin encodes a protein exhibiting about 40% identity with the human amino acid sequence set forth in SEQ ID NO:2.
- 6. An isolated nucleic acid sequence according to claim 5, wherein the DNA of murine origin has substantially the nucleic acid sequence set forth in SEQ ID NO:3.
- 7. A recombinant expression vector comprising a nucleic acid sequence according to claim 1.
- 8. A recombinant expression vector according to claim 7, wherein the nucleic acid sequence is a cDNA sequence.
- 9. A recombinant expression vector according to claim 8, wherein the cDNA is of human origin.
- 10. A recombinant expression vector according to claim 8, wherein the cDNA is of murine origin.
- 11. A recombinant expression vector according to claim 9, wherein the vector is a plasmid.
- 12. A recombinant expression vector according to claim 10, wherein the vector is a plasmid.
- 13. A host cell capable of expressing B7 activation antigen transformed by a recombinant expression vector according to claim 11.
- 14. A host cell capable of expressing B7 activation antigen transformed by a recombinant expression vector according to claim 12.
- 15. A substantially pure nucleic acid sequence coding for at least a portion of the coding region of the B7 B lymphocyte activation antigen set forth in SEQ ID NO:2 comprising amino acids −34 to 254.
- 16. A substantially pure nucleic acid sequence according to claim 15 wherein the nucleic acid is a DNA molecule of human origin.
- 17. A substantially pure nucleic acid sequence according to claim 16, coding for a soluble form of the B7 activation antigen.
- 18. A recombinant expression vector comprising a nucleic acid sequence according to claim 17.
- 19. A host cell capable of expressing B7 activation antigen transformed by a recombinant expression vector according to claim 18.
- 20. A substantially pure, recombinant protein expressed by a host cell according to claim 19.
- 21. A substantially pure nucleic acid sequence coding for a B7 activation antigen which is identical with at least about 40% of the amino acids sequence set forth in SEQ ID NO:2 comprising amino acids −1 to 254.
- 22. A substantially pure nucleic acid sequence according to claim 21 of human origin and coding for the amino acid sequence set forth in SEQ ID NO:2.
- 24. A substantially pure nucleic acid sequence according to claim 21 of murine origin and coding for the amino acid sequence set forth in SEQ ID NO:3.
- 25. A recombinant expression vector comprising a nucleic acid sequence according to claim 24.
- 26. A host cell capable of expressing B7 activation antigen transformed by a recombinant expression vector according to claim 25.
- 27. A recombinant protein expressed by a host cell according to claim 26.
- 28. A substantially pure nucleic acid sequence comprising the nucleic acid sequence substantially as shown in SEQ ID NO:1 encoding a human B7 activation antigen.
- 29. A substantially pure nucleic acid sequence comprising the nucleic acid sequence substantially as shown in SEQ ID NO:3 encoding a murine B7 activation antigen.
- 30. A substantially pure B7 protein.
- 31. A protein according to claim 30 which is of human origin.
- 32. A protein according to claim 31 having the amino acid sequence set forth in SEQ ID NO: 2 or a fragment, mutant or variant thereof capable of either enhancing or suppressing an activated T cell mediated immune response.
- 33. A protein according to claim 30 which is of murine origin.
- 34. A protein according to claim 33 having the amino acid sequence set forth in SEQ ID NO: 4 or a fragment, mutant or variant thereof capable of either enhancing or suppressing an activated T cell mediated immune response.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part of copending U.S. application U.S. Ser. No. 07/591,300, filed on Oct. 1, 1990.
GOVERNMENT RIGHTS TO INVENTION
[0002] This invention was made with Government support under National Institutes of Health Grants CA-34183 and CA-40216 and Public Health Services Grant 5KO8 CA-01105 awarded by the National Cancer Institute, Department of Health and Human Services. The Government therefore has certain rights in this invention.
Continuations (3)
|
Number |
Date |
Country |
Parent |
09522206 |
Mar 2000 |
US |
Child |
10126088 |
Apr 2002 |
US |
Parent |
08153262 |
Nov 1993 |
US |
Child |
09522206 |
Mar 2000 |
US |
Parent |
07751306 |
Aug 1991 |
US |
Child |
08153262 |
Nov 1993 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
07591300 |
Oct 1990 |
US |
Child |
07751306 |
Aug 1991 |
US |